Trials
Search / Trial NCT06420531

Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · May 14, 2024

Apply for Trial

Trial Information

Current as of March 13, 2025

Recruiting

Keywords

ClinConnect Summary

The MAGIC trial is studying how different amounts of human milk can affect the growth and body composition of babies who were born moderately preterm, meaning they were born between 27 and 31 weeks of pregnancy. This research is important because these babies often need special care to help them grow strong and healthy after birth. The trial involves feeding these infants between 180 to 200 milliliters of human milk for every kilogram of their body weight each day, and it aims to see how this diet influences their development.

To be part of this study, babies need to be born at a gestational age between 27 and 31 weeks and weigh 1500 grams or less at birth. They also need to be fed human milk for the first 14 days after birth and be able to take in enough milk to meet feeding goals during that time. Unfortunately, babies with certain serious health issues or those who were fed formula during their first two weeks won't be eligible to join. For those who participate, the trial will help researchers learn more about the best ways to support the growth of preterm infants, which could lead to better health outcomes for these vulnerable babies.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Gestational age between 27 0/7 and 31 6/7 weeks
  • • Birthweight of 1500 grams or less
  • • Human milk feeding during the first 14 days after birth
  • • Full enteral feeding (120mL/kg/day or more) within the first 14 days after birth
  • Exclusion Criteria:
  • • Necrotizing enterocolitis stage 2 or greater
  • • Spontaneous intestinal perforation
  • • Major congenital/chromosomal anomalies
  • • Terminal illness requiring limited or withheld support
  • • Intention to restrict fluid intake after the first 14 postnatal days due to the presence of a symptomatic patent ductus arteriosus (PDA)
  • • Any formula feeding within the first 14 days after birth

Trial Officials

Ariel A. Salas, MD, MSPH

Principal Investigator

UAB Hospital

About University Of Alabama At Birmingham

The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.

Locations

Birmingham, Alabama, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0